oral COVID-19 vaccine(Rapid Dose Therapeutics/McMaster University)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameoral COVID-19 vaccine(Rapid Dose Therapeutics/McMaster University)
Drug Alias NameSARS-CoV-2 Spike Glycoprotein Inhibitor (Rapid Dose Therapeutics/McMaster University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Application > Therapeutic vaccine
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMcMaster HealthLabs
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRapid Dose Therapeutics IncMcMaster HealthLabs
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A